Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab plus BCG in NMIBC (ABC Trial)
NCT03892642Phase 2Completed
- Sponsor
- University of Oklahoma
- Start
- May 2019
- Primary completion
- Mar 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab in Non-muscle-invasive bladder cancer (NMIBC), sponsored by University of Oklahoma. Primary endpoint: Proportion of Patients Receiving Complete Induction Course at 8 weeks. Started May 2019; status: completed.
02
Drugs
avelumab
03
Conditions
Non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT03892642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03892642.